Clinical Data Spotlight on Glooko’s EndoTool IV in Multi-Hospital Deployment

According to a recent LinkedIn post from Glooko, new clinical data on EndoTool IV, developed by Monarch Medical Technologies, were presented at the 2026 American Association of Clinical Endocrinology Annual Meeting. The presentation by Glooko’s Paul Chidester, M.D., and Advocate Health Wake Forest Baptist Hospital’s Joe Aloi, M.D., focused on inpatient glycemic management outcomes.

The post highlights findings that EndoTool IV achieved a reported 98% reduction in severe hypoglycemia compared with paper protocols across Advocate Health’s 19-hospital system. The shared link suggests Glooko is positioning EndoTool IV as a scalable solution for safer glycemic control at health-system level.

For investors, these reported results could indicate growing clinical validation of Glooko’s hospital-focused diabetes management technology and support its value proposition in enterprise health systems. Demonstrated safety improvements in a multi-hospital deployment may strengthen Glooko’s competitive stance in inpatient glycemic management and could support future adoption discussions with large providers and health networks.

If such outcomes are replicated and recognized in clinical and payer communities, Glooko may be able to leverage the data in commercialization, pricing, and partnership negotiations. The emphasis on health-system scale in the post also suggests a strategic focus on broad deployments, which, if successful, could translate into more recurring revenue opportunities and deeper integration within hospital workflows.